Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?Javier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
Med Hypotheses 64:342-9. 2005
....
Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
Med Hypotheses 64:997-1001. 2005
....
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail"Javier A Menendez
Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia Spain
Clin Transl Oncol 8:812-20. 2006
....
Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesisJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 Unviersity Place, Evanston, IL 60201, USA
Med Hypotheses 64:337-41. 2005
....
Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9)Javier A Menendez
Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia, Spain
Curr Pharm Biotechnol 7:495-502. 2006
..Only then we will know whether the old "Mediterranean dietary traditions" will become a new molecular approach in the management of cancer disease...
In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cellsJavier A Menendez
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
J Cell Biochem 94:1-4. 2005
..These findings, altogether, support the "metabolic oncogene" theory for FAS overexpression in cancer cells...
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancerCristina Oliveras-Ferraros
Catalan Institute of Oncology ICO, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
Int J Oncol 33:1165-76. 2008
....
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)Javier A Menendez
Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
BMC Cancer 8:377. 2008
..We here investigated the anti-HER2 effects of phenolic fractions directly extracted from Extra Virgin Olive Oil (EVOO) in cultured human breast cancer cell lines...
Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicityJavier A Menendez
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute ENHRI, Evanston, IL 60201, USA
Int J Cancer 115:19-35. 2005
....
Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformationJavier A Menendez
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
Mol Carcinog 41:164-78. 2004
..Our observations strongly suggest that inhibition of FAS activity may provide a new molecular avenue for chemotherapeutic prevention and/or treatment of Her-2/neu-related breast carcinomas...
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare, 1001 University Place, Evanston, IL 60201, USA
Proc Natl Acad Sci U S A 101:10715-20. 2004
....
Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205Sílvia Cufí
Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute Girona, Catalonia, Spain These authors have equally contributed to this research and are listed in random order
Cell Cycle 11:1235-46. 2012
....
Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3Cristina Oliveras-Ferraros
Catalan Institute of Oncology, 2Girona Biomedical Research Institute, Girona, Catalonia, Spain
Int J Oncol 38:1533-47. 2011
..Oleaceae secoiridoids could provide a valuable phytochemical platform for the design of more pharmacologically active second-generation phytopharmaceutical anti-breast cancer molecules with a unique mode of action...
Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogeneJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
J Natl Cancer Inst 97:1611-5. 2005
..Concurrent treatments of Her-2/neu-overexpressing cancer cells with GLA and the anti-Her-2/neu antibody trastuzumab led to synergistic increases in apoptosis and reduced growth and colony formation...
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)Cristina Oliveras-Ferraros
Catalan Institute of Oncology ICO, E 17007 Girona, Catalonia, Spain
Int J Oncol 37:669-78. 2010
....
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growthAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO, Catalonia, Spain
J Cell Physiol 226:52-7. 2011
..These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib...
Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cellsAlejandro Vazquez Martin
Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
Int J Oncol 31:769-76. 2007
....
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)Cristina Oliveras-Ferraros
Catalan Institute of Oncology ICO, Avenida de Francia s n, Girona, Catalonia, Spain
Biochem Biophys Res Commun 397:27-33. 2010
..Intrinsic genetic plasticity to efficiently drive the emergence of the CD44(pos)/CD24(neg/low) mesenchymal phenotype may account for de novo resistance to HER2 targeting therapies in basal-like BC carrying HER2 gene amplification...
Metformin: multi-faceted protection against cancerSonia del Barco
Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
Oncotarget 2:896-917. 2011
..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...
Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatusAlejandro Vazquez-Martin
Unit of Translational Research, Catalan Institute of Oncology Girona, Girona, Spain
Cell Cycle 10:1295-302. 2011
....
Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linoleniJavier A Menendez
Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
Int J Oncol 24:1369-83. 2004
....
Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicalsAlejandro Vazquez-Martin
Catalan Institute of Oncology, Girona, Catalonia, Spain
Rejuvenation Res 15:3-21. 2012
....
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cellsCristina Oliveras-Ferraros
Unit of Translational Research, Catalan Institute of Oncology, Girona, Catalonia, Spain
Invest New Drugs 30:846-52. 2012
....
Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contraEugeni Lopez-Bonet
Department of Pathology, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
Int J Oncol 36:107-15. 2010
..These findings warrant forthcoming studies to confirm both the accuracy and the prognostic value of PP-mTOR(Ser2481) as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas...
Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancerJavier A Menendez
Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
Aging (Albany NY) 3:1063-77. 2011
....
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesionsAlejandro Vazquez-Martin
Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
Drug Resist Updat 14:212-23. 2011
....
AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancerLuciano Vellon
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
Oncogene 24:3759-73. 2005
..This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells...
A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at tJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, and Department of Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
Eur J Cancer 42:2425-32. 2006
..OA-induced transcriptional repression of Her-2/neu through the action of PEA3 protein at the promoter level may represent a novel mechanism linking "Mediterranean diet" and cancer...
Mediterranean diet, olive oil and cancerRamon Colomer
Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
Clin Transl Oncol 8:15-21. 2006
....
Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patientsAlejandro Vazquez-Martin
Catalan Institute of Oncology, Health Services Division of Catalonia, Catalonia, Spain
Int J Oncol 35:1369-76. 2009
....
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpressionJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
J Clin Oncol 24:3735-46. 2006
..CONCLUSION: We demonstrate that assessment of HRG expression and Her-2 activation define a particular breast cancer patient population for which trastuzumab plus CDDP or taxol are extremely efficient without Her-2 overexpression...
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatmentCristina Oliveras-Ferraros
Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
Oncol Rep 27:1887-92. 2012
....
Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs)Alejandro Vazquez-Martin
Unit of Translational Research, Catalan Institute of Oncology Girona, Girona Biomedical Research Institute, Girona, Spain
Cell Cycle 10:3140-52. 2011
..Nucleolar- and NOR-associated P-Raptor (Ser706) may physically link mTORC1 signaling to ever-growing nucleolus plurifunctionality including ribosome biogenesis, cell stress sensor and cell cycle/aging control...
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genesJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Int J Mol Med 18:1081-7. 2006
....
An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer valueRuth Lupu
Department of Medicine, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Clin Transl Oncol 10:219-26. 2008
..This "C75-sensitivity test" might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer...
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapiesCristina Oliveras-Ferraros
Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
Biochem Biophys Res Commun 407:412-9. 2011
..Our current findings may be extremely helpful to design successful combinatorial strategies aimed to circumvent the occurrence of de novo resistance to HER2-directed drugs using survivin antagonists...
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressorAlejandro Vazquez-Martin
Catalan Institute of Oncology Health Services Division of Catalonia, Catalonia, Spain
Cell Cycle 8:3679-83. 2009
....
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line modCristina Oliveras-Ferraros
Unit of Translational Research, Catalan Institute of Oncology Girona, ICO Girona, E 17007 Girona, Catalonia, Spain
Int J Oncol 39:1455-79. 2011
....
Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
Oncol Rep 12:411-22. 2004
..We suggest that pharmacological inhibition of FAS activity is a novel molecular approach to enhance the cytotoxic effects of existing chemotherapeutic agents in human breast cancer...
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cellsAlejandro Vazquez-Martin
Catalan Institute of Oncology, Girona ICO Girona, Dr Josep Trueta University Hospital, Ctra França s n, 17007, Girona, Catalonia, Spain
Breast Cancer Res Treat 126:355-64. 2011
....
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathwayJavier A Menendez
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Oncogene 24:761-79. 2005
..The identification of a 'CYR61-alphavbeta3 autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alphavbeta3 may simultaneously prevent breast cancer angiogenesis, growth, and chemoresistance...
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesisJavier A Menendez
Translational Research Unit, Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Josep Trueta University Hospital of Girona, 17, 007 Girona, Catalonia, Spain
Nat Rev Cancer 7:763-77. 2007
..FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer...
Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cellsAlejando Vazquez Martin
Catalan Institute of Oncology Health Services Division of Catalonia, 17007 Girona, Catalonia, Spain
Oncol Rep 18:973-80. 2007
....
Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expreJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201, USA
J Cell Biochem 94:857-63. 2005
....
A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cellsLuciano Vellon
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
Mol Carcinog 45:795-804. 2006
..Collectively, these results strongly suggest the existence of a bidirectional molecular connection alpha(v)beta(3)-ERK1/ERK2 MAPK that would regulate breast cancer cells survival and proliferation...
Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damageJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Int J Oncol 26:649-59. 2005
....
Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181aCristina Oliveras-Ferraros
Catalan Institute of Oncology Girona ICO Girona, Girona, Catalonia, Spain
Cell Cycle 10:1144-51. 2011
....
Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent mannerLuciano Vellon
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL, USA
Differentiation 75:819-30. 2007
....
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cellsAlejandro Vazquez-Martin
Catalan Institute of Oncology, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
Oncol Rep 25:135-40. 2011
....
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) statusAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
Cell Cycle 9:3807-14. 2010
....
The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cellsAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO Girona, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
Biochem Biophys Res Commun 380:638-43. 2009
..These results reveal for the first time that PP-mTOR(Ser2481) may be unexpectedly involved in the terminal stages of cytokinesis...
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)Laura Ferrer Soler
Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
Int J Mol Med 20:3-10. 2007
....
Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistanceJose Manuel Fernandez-Real
Department of Diabetes, Endocrinology and Nutrition, Institutd Investigació Biomédica de Girona, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Girona, Catalonia, Spain
Diabetes 59:1506-11. 2010
..The aim of this study was to determine whether circulating FASN could be a biomarker of overnutrition-induced metabolic stress and insulin resistance in common metabolic disorders...
Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cellsJavier A Menendez
Foundation of the Recerca Bio Medical Institute of Girona Dr Josep Trueta, University Hospital of Girona, Dr Josep Trueta, Girona, Catalonia, Spain
Curr Opin Clin Nutr Metab Care 9:346-57. 2006
..This review documents our rapidly changing perspectives on the function of fatty acid synthase-catalyzed endogenous fatty acid biogenesis in cancer biology...
The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survivalJavier A Menendez
Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Int J Oncol 26:1507-15. 2005
....
AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid SynthaseCristina Oliveras-Ferraros
Catalan Institute of Oncology, Girona ICO Girona, Hospital de Girona Dr Josep Trueta, Ctra França s n, E 17007 Girona, Catalonia, Spain
Biochem Biophys Res Commun 378:488-93. 2009
..FASN release might represent a previously unrecognized mechanism through which AMPK monitor and restores cellular energy state in response to increasing AMP/ATP ratios...
Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?Javier A Menendez
Department of Medicine, Breast Cancer Translational Research Program, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, Illinois 60201, USA
Exp Biol Med (Maywood) 230:151-4. 2005
Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancerJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA
Drug News Perspect 18:375-85. 2005
..Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185(Her-2/neu) oncoprotein...
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?Ruth Lupu
Department of Medicine, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, Illinois 60201, USA
Endocrinology 147:4056-66. 2006
....
Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75Teresa Puig
Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
Breast Cancer Res Treat 109:471-9. 2008
..Our results establish EGCG as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug...
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of schedulingCristina Oliveras-Ferraros
Metabolism and Cancer Laboratory, Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
Int J Oncol 32:113-20. 2008
..The synergism that we have observed may explain the favorable clinical responses that have been achieved in clinical studies, in which patients are administered PTX first, and then GEM...
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugsBruna Corominas-Faja
Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
Aging (Albany NY) 4:480-98. 2012
....
Her-2/neu-induced "cytokine signature" in breast cancerAlejandro Vazquez-Martin
Fundación Privada de Investigación Biomédica de Girona Dr Joseph Trueta Instituto Catalá de Oncología de Girona, Catalonia, Spain
Adv Exp Med Biol 617:311-9. 2008
....
Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Arch Immunol Ther Exp (Warsz) 52:414-26. 2004
....
Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)Javier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Breast Cancer Res Treat 84:183-95. 2004
..To the best of our knowledge this is the first study demonstrating that FAS is playing an active role in HER -2/ neu -induced breast cancer chemotherapy resistance...
Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancerAlejandro Vazquez Martin
Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Avenida de Francia s n, 17007 Girona, Catalonia, Spain
Eur J Cancer 43:1117-24. 2007
....
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cellsAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, Girona, Catalonia, Spain
Cell Cycle 8:88-96. 2009
..The importance of mTOR/p70S6K1-sensed ROS status at mediating the anti-oncogenic effects of metformin might represent a previously unrecognized linkage molecularly connecting its anti-aging and anti-cancer actions...
Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancerJavier A Menendez
Catalan Institute of Oncology, Girona Biomedical Research Institute, Hospital Universitari de Girona Josep Trueta, Girona, Catalonia, Spain
Clin Chem 55:425-38. 2009
..An emerging paradigm supports the notion that deregulation of fatty acid synthase (FASN)-catalyzed de novo FA biogenesis could play a central role in the pathogenesis of metabolic diseases sharing the hallmark of insulin-resistance...
Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?Ruth Lupu
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Curr Pharm Biotechnol 7:483-93. 2006
..5 A resolution X-ray crystallographic map of mammalian FASN, will direct the foundation of a new family of chemotherapeutic agents in cancer history...
Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarraysJavier A Menendez
Girona Biomedical Research Institute, Medical Oncology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
Int J Mol Med 22:433-9. 2008
....
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
PLoS ONE 4:e6251. 2009
..Therapeutic targeting autophagosome formation/function might represent a novel molecular avenue to reduce the emergence of Tzb resistance in HER2-dependent breast carcinomas...
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaBJavier A Menendez
Department of Medicine, Evanston Northwestern Research Institute, Evanston, IL 60201, USA
Int J Oncol 24:591-608. 2004
....
RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Int J Mol Med 15:33-40. 2005
....
Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectivesJavier A Menendez
Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
Biochim Biophys Acta 1801:381-91. 2010
....
The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesisAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO, Girona Biomedical Research Institute IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Catalonia, Spain
J Cell Biochem 105:1147-52. 2008
..Our findings not only confirm a non-oncogenic role for HER2 in the process of adipose differentiation but further suggest that HER2 might represent a previously unrecognized target to manage obesity via the lipogenic enzyme FASN...
The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesisAlejandro Vazquez-Martin
Catalan Institute of Oncology ICO and Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital, E 17007 Girona, Catalonia, Spain
Cell Cycle 8:2385-98. 2009
....
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cellsJavier A Menendez
Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA
Oncogene 23:4945-58. 2004
....
Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?Javier A Menendez
Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Dr, Josep Trueta, University Hospital of Girona, Catalonia, Spain
Breast Cancer Res 9:111. 2007
....
Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profilingEugeni Lopez-Bonet
Department of Pathology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
Oncol Rep 20:1369-74. 2008
..Forthcoming studies should definitely determine if the clinico-pathological features of NEBC indeed represent an independent good-prognosis subgroup of BC gene signature...
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancerJoan Brunet
Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
Mol Carcinog 47:157-63. 2008
..Alternatively, new forthcoming ACCA inhibitors may be relevant in the management of BRCA1-dependent breast cancer susceptibility and development...